San Diego ­­– December 8, 2016 – Cooley advised Xencor on its $126.5 million shelf-takedown offering of 5,272,750 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares.

Xencor, which trades on the NASDAQ Global Market under the symbol "XNCR," is a clinical stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Xencor uses its proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.